Aflibercept injection for polypoidal choroidal vasculopathy
Part of Eyes & vision clinical trials.
This study tests a new higher-dose version of an eye injection called aflibercept (Eylea) for people with a specific type of wet age-related macular degeneration called polypoidal choroidal vasculopathy (PCV). The goal is to see if this treatment is effective, long-lasting, and safe, and it may help improve or preserve your vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years of age or older.
- You have a confirmed diagnosis of a specific type of wet age-related macular degeneration called polypoidal choroidal vasculopathy (PCV).
- You have not received any prior treatment for PCV in the study eye (like anti-VEGF injections, laser, or photodynamic therapy).
- Your blood pressure must be reasonably controlled (below 160/95).
- You have no other eye diseases in the study eye that could affect vision or require surgery during the study.
- If you are a woman who can become pregnant, you must not be pregnant or breastfeeding and must agree to use two forms of birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a higher dose of aflibercept (a drug that blocks abnormal blood vessel growth) for people with a specific form of wet age-related macular degeneration called polypoidal choroidal vasculopathy. The goal is to see if a personalized treatment plan with this stronger dose is safe and effective for those who have not been treated before.
This study tests a personalized treatment plan using an investigational drug called faricimab for people who have a specific type of wet age-related macular degeneration known as polypoidal choroidal vasculopathy. The goal is to see if adjusting the time between injections based on your individual needs can safely dry up fluid in the retina and improve vision.
This study follows patients receiving aflibercept 8 mg injections in the eye to treat wet age-related macular degeneration (nAMD), a condition that blurs central vision. The goal is to understand how well this treatment works and its safety in routine medical practice.
This trial tests a new eye injection called AL-001 for people with wet age-related macular degeneration (AMD), a condition that causes blurry vision. The injection aims to stop the growth of abnormal blood vessels in the eye and improve vision.
This study tests a higher dose of a drug called aflibercept, given as eye injections, for people with untreated wet age-related macular degeneration (AMD). The goal is to see if it can improve vision and how often it needs to be given.
This trial studies whether aflibercept injections can help when “wet” age-related macular degeneration is recurring or not fully going away. It focuses on adults who have already had ranibizumab and still have measurable vision in the study eye.
Hear when a new Polypoidal Choroidal Vasculopathy (PCV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.